Need professional-grade analysis? Visit stockanalysis.com
$37.48B
77.95
7,676
0.28%
Galderma Group N (GALD) trades on SIX Swiss Exchange in CHF. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at CHF155.05, down 1.15% from the previous close.
Over the past year, GALD has traded between a low of CHF77.37 and a high of CHF167.80. The stock has gained 102.7% over this period. It is currently 6.5% below its 52-week high.
Galderma Group N has a market capitalization of $37.48B, with a price-to-earnings ratio of 77.95 and a dividend yield of 0.28%.
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Side-by-side comparison against top Healthcare peers.